127 related articles for article (PubMed ID: 37317583)
41. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
42. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate.
Fatum M; McVeigh E; Child T
Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119
[TBL] [Abstract][Full Text] [Related]
43. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
44. Does type of cancer affect ovarian response in oncofertility patients?
Hussein RS; Zhao Y; Khan Z
J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101944. PubMed ID: 33069914
[TBL] [Abstract][Full Text] [Related]
45. Fertility preservation among young breast cancer patients: A single-center experience in China.
Wan Q; Han L; Liu J; Li H; Li Y; Long QM; Tan L; Li JJ
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):827-830. PubMed ID: 34507656
[TBL] [Abstract][Full Text] [Related]
46. Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome.
Talaulikar VS; Conway GS; Pimblett A; Davies MC
Fertil Steril; 2019 Mar; 111(3):505-509. PubMed ID: 30598170
[TBL] [Abstract][Full Text] [Related]
47. Combining fertility preservation procedures to spread the eggs across different baskets: a feasibility study.
Delattre S; Segers I; Van Moer E; Drakopoulos P; Mateizel I; Enghels L; Tournaye H; De Vos M
Hum Reprod; 2020 Nov; 35(11):2524-2536. PubMed ID: 32951035
[TBL] [Abstract][Full Text] [Related]
48. Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.
Manuel SL; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Pavone ME
J Assist Reprod Genet; 2020 Mar; 37(3):699-708. PubMed ID: 31828481
[TBL] [Abstract][Full Text] [Related]
49. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield.
Hourvitz A; Yerushalmi GM; Maman E; Raanani H; Elizur S; Brengauz M; Orvieto R; Dor J; Meirow D
Reprod Biomed Online; 2015 Oct; 31(4):497-505. PubMed ID: 26278808
[TBL] [Abstract][Full Text] [Related]
50. Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer.
Porcu E; Cillo GM; Cipriani L; Sacilotto F; Notarangelo L; Damiano G; Dirodi M; Roncarati I
J Assist Reprod Genet; 2020 Mar; 37(3):709-715. PubMed ID: 31872386
[TBL] [Abstract][Full Text] [Related]
51. Ovarian response after random-start controlled ovarian stimulation to cryopreserve oocytes in cancer patients.
Campos APC; Geber GP; Hurtado R; Sampaio M; Geber S
JBRA Assist Reprod; 2018 Nov; 22(4):352-354. PubMed ID: 30264947
[TBL] [Abstract][Full Text] [Related]
52. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen.
Balkenende EM; Dahhan T; Linn SC; Jager NG; Beijnen JH; Goddijn M
Hum Reprod; 2013 Apr; 28(4):953-9. PubMed ID: 23335608
[TBL] [Abstract][Full Text] [Related]
53. Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients.
Moraes CC; Marinho VFW; Campos ALM; Guedes JS; Xavier ÉBS; Caetano JPJ; Marinho RM
JBRA Assist Reprod; 2019 Apr; 23(2):91-98. PubMed ID: 30875168
[TBL] [Abstract][Full Text] [Related]
54. Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls.
Decanter C; Robin G; Mailliez A; Sigala J; Morschhauser F; Ramdane N; Devos P; Dewailly D; Leroy-Martin B; Keller L
Reprod Biomed Online; 2018 May; 36(5):543-551. PubMed ID: 29506861
[TBL] [Abstract][Full Text] [Related]
55. [Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors].
Dadoun Y; Azaïs H; Keller L; d'Orazio E; Collinet P; Decanter C
Gynecol Obstet Fertil Senol; 2017 Jun; 45(6):359-365. PubMed ID: 28506797
[TBL] [Abstract][Full Text] [Related]
56. Fertility preservation in female patients with hematological disorders.
Wu D; Shen H
BMC Pregnancy Childbirth; 2022 Jan; 22(1):61. PubMed ID: 35065646
[TBL] [Abstract][Full Text] [Related]
57. Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy.
Cohen Y; Tannus S; Volodarsky-Perel A; Son WY; Tulandi T; Buckett W
Reprod Sci; 2020 Dec; 27(12):2257-2264. PubMed ID: 32617879
[TBL] [Abstract][Full Text] [Related]
58. Oocyte cryopreservation for fertility preservation in women with ovarian endometriosis.
Kim SJ; Kim SK; Lee JR; Suh CS; Kim SH
Reprod Biomed Online; 2020 Jun; 40(6):827-834. PubMed ID: 32295746
[TBL] [Abstract][Full Text] [Related]
59. Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type.
Lefebvre T; Mirallié S; Leperlier F; Reignier A; Barrière P; Fréour T
Reprod Biomed Online; 2018 Aug; 37(2):201-207. PubMed ID: 29784618
[TBL] [Abstract][Full Text] [Related]
60. Fertility preservation after gonadotoxic treatments for cancer and autoimmune diseases.
Saito S; Yamada M; Yano R; Takahashi K; Ebara A; Sakanaka H; Matsumoto M; Ishimaru T; Utsuno H; Matsuzawa Y; Ooka R; Fukuoka M; Akashi K; Kamijo S; Hamatani T; Tanaka M
J Ovarian Res; 2023 Aug; 16(1):159. PubMed ID: 37563616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
